UN official sees positives in China鈥檚 fight on corrupt firms
Print Edition
An intensifying crackdown on corruption in China is a positive development that should be welcomed by companies doing business there, and not be a source of concern, a senior UN crime-fighting official said yesterday.
Some foreign firms in China are getting increasingly jumpy about a spate of corruption and anti-trust investigations by Chinese authorities and are hiring lawyers to make sure their operations comply with the law.
Graft investigations have targeted the pharmaceutical industry while authorities have also launched a major probe into China’s leading oil and gas company.
Dimitri Vlassis, head of the corruption and economic crime branch of the Vienna-based UN Office on Drugs and Crime (UNODC), said corporate leaders should use the campaign against graft as an opportunity for reform.
“The (Chinese) authorities are taking this issue very, very seriously and they have increased their anti-corruption drive more generally in visible ways in the past couple of years,” he said.
Companies should welcome this and review internal processes, he said, but make sure this was not simply an issue of complying with the law.
“It is also a matter of actually doing the right thing and engaging in competition based on a set of ethical principles, ethical behavior,” Vlassis added, advocating corporate zero-tolerance of graft.
Chinese President Xi Jinping, who took office in March, has made fighting corruption a central theme of his administration after a series of scandals.
“What I see are very important and consistently determined steps forward,” Vlassis said.
The biggest foreign firm in the spotlight is British drugmaker GlaxoSmithKline, which Chinese police have accused of funneling up to 3 billion yuan (US$489.92 million) to travel agencies to facilitate bribes to doctors to boost the sale of its medicines.
GSK has said some of its senior Chinese executives appeared to have broken the law and that it has zero-tolerance for bribery.
Last month, Xinhua news agency reported that China was intensifying its investigation into bribery in the pharmaceutical and medical services sector with a fresh three-month investigation.
“It is not only China. The numbers of countries that are cracking down is increasing and it is widespread,” Vlassis said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
